文献速递眼底病与葡萄膜炎

BCAT1激活重编程支链氨基酸代谢并通过表观遗传促进糖尿病视网膜病变炎症

BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

研究探讨支链氨基酸代谢重塑及其对糖尿病视网膜病变进展的作用。发现Bcat1在Müller细胞中高表达且糖尿病条件下活性增加,通过降低α-酮戊二酸提高炎症基因启动子H3K4me3水平促进炎症;Bcat1抑制剂BAY-069和ERG240可减少糖尿病视网膜炎症基因表达和血管渗漏。

要点

  • Bcat1主要表达于Müller细胞,糖尿病条件下活性增加,重编程支链氨基酸分解代谢并上调Il6和Tnf-α。
  • Plk4介导的Bcat1苏氨酸333位磷酸化负向调控其活性。
  • Bcat1抑制剂BAY-069和ERG240显著减少糖尿病视网膜炎症基因表达和血管渗漏。

核心结论

  • Bcat1激活介导Müller细胞支链氨基酸代谢重塑并表观遗传诱导视网膜炎症,为糖尿病视网膜病变提供潜在治疗靶点。
  • 糖尿病和糖尿病视网膜病变可能不仅由高血糖驱动,还由氨基酸代谢异常驱动。

研究设计与样本

  • 使用单细胞测序数据和免疫荧光分析视网膜Bcat1和Bcat2表达。
  • 通过靶向代谢组学评估Müller细胞中Bcat1介导的支链氨基酸代谢重塑。
  • 采用染色质免疫沉淀检查炎症基因启动子组蛋白甲基化。
  • 利用RNA测序和激酶筛选试验 delineate Bcat1活性的磷酸化调控。
  • 建立糖尿病小鼠模型并用Bcat1特异性抑制剂治疗,评估视网膜炎症和血管渗漏。

主要发现

  • Bcat1主要表达于Müller细胞,糖尿病条件下活性增加,导致支链氨基酸分解代谢重塑和炎症基因Il6、Tnf-α上调。
  • Bcat1活性受Plk4介导的苏氨酸333位磷酸化负向调控。
  • 高糖处理的Müller细胞中Bcat1活性升高降低α-酮戊二酸,增加炎症基因启动子H3K4me3水平,进一步促进视网膜炎症。
  • Bcat1化学抑制剂BAY-069和ERG240显著减少糖尿病视网膜炎症基因表达和血管渗漏。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate how branched-chain amino acid (BCAA) metabolism is remodeled and to determine its contribution to diabetic retinopathy progression. METHODS: We analyzed Bcat1 and Bcat2 expression in the retina using single-cell sequencing data and immunofluorescence. Bcat1-mediated remodeling of BCAA metabolism was assessed via targeted metabolomics in Müller cells. We performed chromatin immunoprecipitation (ChIP) to examine histone methylation at inflammatory gene promoters. Additionally, we utilized RNA sequencing and kinase screening assays to delineate phosphorylation regulation of Bcat1 activity. In vivo, we established diabetic mouse models and treated them with Bcat1-specific inhibitor to evaluate retinal inflammation and vascular leakage. RESULTS: Bcat1 was predominantly expressed in Müller cells and exhibited increased activity under diabetic conditions, leading to a remodeling of BCAA catabolism and upregulation of inflammatory genes (interleukin 6 [Il6] and tumor necrosis factor-α [Tnf-α]). Bcat1 activity was negatively regulated by polo-like kinase 4 (Plk4)-mediated phosphorylation at threonine 333. In high glucose-treated Müller cells, elevated Bcat1 activity reduced α-ketoglutarate (α-KG), a critical substrate for histone demethylation reactions, resulting in higher histone H3 lysine 4 trimethylation (H3K4me3) levels at inflammatory gene promoters, and further boosted retinal inflammation. Treatment with chemical Bcat1 inhibitors (BAY-069 and ERG240) significantly reduced inflammatory gene expression and vascular leakage in diabetic retinas in vivo. CONCLUSIONS: Bcat1 activation mediates BCAA metabolism remodeling in Müller cells and epigenetically induces retinal inflammation, which offers a potential therapeutic target for diabetic retinopathy. Diabetes and diabetic retinopathy are potentially driven not only by hyperglycemia but also by dysregulated amino acid metabolism.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Wang J, Yin Z, Yang J, et al. BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2025. PMID: 40530920. doi:10.1167/iovs.66.6.59

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。